



**Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease.**

|                               |   |
|-------------------------------|---|
| Journal:                      | <i>European Stroke Journal</i>  |
| Manuscript ID                 | Draft   |
| Manuscript Type:              | Protocol  |
| Date Submitted by the Author: | n/a   |
| Complete List of Authors:     | <p>Wardlaw, Joanna; University of Edinburgh, Centre for Clinical Brain Sciences<br/>           Bath, Philip; University of Nottingham, Faculty of Medicine &amp; Health Sciences<br/>           Doubal, Fergus; University of Edinburgh, Centre for Clinical Brain Sciences<br/>           Heye, Anna; The University of Edinburgh, Edinburgh CLinical Trials Unit, Usher Institute<br/>           Sprigg, Nikola; University of Nottingham, Stroke, Division of Clinical Neuroscience<br/>           Woodhouse, Lisa; University of Nottingham School of Medicine, Division of Clinical Neuroscience<br/>           blair, Gordon; The University of Edinburgh, Centre for Clinical Brain Sciences<br/>           Appleton, Jason; University of Nottingham, Division of Clinical Neurosciences<br/>           Cvoro, Vera; The University of Edinburgh, Centre for Clinical Brain Sciences<br/>           England, Timothy; University of Nottingham, Vascular Medicine, Division of Medical Sciences and GEM<br/>           Hassan, Ahamad; Leeds General Infirmary, Department of Neurology<br/>           Werring, David; University College London Institute of Neurology, Stroke Research Centre<br/>           Montgomery, Alan; University of Nottingham</p> |
| Keywords:                     | randomised clinical trial, isosorbide mononitrate, cilostazol, small vessel disease, lacunar stroke   |
| Abstract:                     | <p>Background: Small vessel disease (SVD) causes a quarter of ischaemic strokes (lacunar subtype), up to 45% of dementia either as vascular or mixed types, cognitive impairment and physical frailty. However, there is no specific treatment to prevent progression of SVD.</p> <p>Aim: We designed the LACunar Intervention Trial-2 (LACI-2) to test feasibility of a large trial testing cilostazol and/or isosorbide mononitrate (ISMN) by demonstrating adequate participant recruitment and retention in follow-up, drug tolerability, safety, and confirm outcome event rates required to power a phase 3 trial.</p> <p>Methods and design: LACI-2 is an investigator-initiated, prospective randomised open label blinded endpoint (PROBE) trial aiming to recruit</p>   |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

|  |   |
|--|---|
|  | <p>400 patients with prior lacunar syndrome due to a small subcortical infarct. We randomise participants to cilostazol v no cilostazol and ISMN or no ISMN, minimising on key prognostic factors. All patients receive guideline-based best medical therapy. Patients commence trial drug at low dose, increment to full dose over 2-4 weeks, continuing on full dose for a year. We follow-up participants to one year for symptoms, tablet compliance, safety, recurrent vascular events, cognition and functional outcomes, Trails B and brain MRI. LACI-2 is registered ISRCTN 14911850, EudraCT 2016-002277-35.</p> <p>Trial Outcome: Primary outcome is feasibility of recruitment and compliance; secondary outcomes include safety (cerebral or systemic bleeding, falls, death), efficacy (recurrent cerebral and cardiac vascular events, cognition on TICS, Trails B) and tolerability.</p> <p>Summary: LACI-2 will determine feasibility, tolerability and provide outcome rates to power a large phase 3 trial to prevent progression of cerebral small vessel disease.</p> |
|  |   |

SCHOLARONE™  
Manuscripts

1  
2  
3 Title: Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced  
4 drugs to prevent progression of cerebral small vessel disease.  
5  
6

7  
8 Authors: The LACI-2 Trial Investigators\*  
9

10  
11 Address for correspondence: Prof JM Wardlaw, Chancellor's Building, University of  
12 Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.  
13

14 Email: joanna.wardlaw@ed.ac.uk  
15

16  
17 Word counts: abstract 250; text 3051; references 46; tables 4; figures 1;  
18  
19

20  
21 Key words: lacunar stroke, small vessel disease, cilostazol, isosorbide mononitrate,  
22 randomised clinical trial  
23  
24  
25  
26  
27

28 \*full list see Appendix.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract:**

*Background:* Small vessel disease (SVD) causes a quarter of ischaemic strokes (lacunar subtype), up to 45% of dementia either as vascular or mixed types, cognitive impairment and physical frailty. However, there is no specific treatment to prevent progression of SVD.

*Aim:* We designed the LACunar Intervention Trial-2 (LACI-2) to test feasibility of a large trial testing cilostazol and/or isosorbide mononitrate (ISMN) by demonstrating adequate participant recruitment and retention in follow-up, drug tolerability, safety, and confirm outcome event rates required to power a phase 3 trial.

*Methods and design:* LACI-2 is an investigator-initiated, prospective randomised open label blinded endpoint (PROBE) trial aiming to recruit 400 patients with prior lacunar syndrome due to a small subcortical infarct. We randomise participants to cilostazol v no cilostazol and ISMN or no ISMN, minimising on key prognostic factors. All patients receive guideline-based best medical therapy. Patients commence trial drug at low dose, increment to full dose over 2-4 weeks, continuing on full dose for a year. We follow-up participants to one year for symptoms, tablet compliance, safety, recurrent vascular events, cognition and functional outcomes, Trails B and brain MRI. LACI-2 is registered ISRCTN 14911850, EudraCT 2016-002277-35.

*Trial Outcome:* Primary outcome is feasibility of recruitment and compliance; secondary outcomes include safety (cerebral or systemic bleeding, falls, death), efficacy (recurrent cerebral and cardiac vascular events, cognition on TICS, Trails B) and tolerability.

*Summary:* LACI-2 will determine feasibility, tolerability and provide outcome rates to power a large phase 3 trial to prevent progression of cerebral small vessel disease.

## Introduction:

Stroke and vascular dementia are increasing in prevalence,<sup>1</sup> have enormous economic and societal costs, share many risk factors, and are major Government targets for health improvement.<sup>2,3</sup> Cerebral small vessel disease (SVD) is a central link between stroke and dementia.<sup>4</sup> It accounts for 20-25% of clinical strokes as either recent small subcortical or 'lacunar' infarcts<sup>5</sup> (hereafter referred to as 'lacunar ischaemic stroke') and most intracerebral haemorrhages in older people,<sup>6</sup> and up to 45% of all dementias, alone or combined with Alzheimer's disease.<sup>7</sup> Patients presenting with a lacunar ischaemic stroke are often younger than with other stroke subtypes,<sup>6</sup> and about a third experience post-stroke cognitive impairment or dementia<sup>8,9</sup> which may restrict their independence, including ability to return to work.<sup>9</sup>

The causes of lacunar ischaemic stroke are still poorly understood.<sup>4</sup> Most appear due to an intrinsic cerebral perforating arteriolar disease. This includes impaired vasoreactivity, increased blood-brain barrier (BBB) permeability and perivascular inflammation, all causing brain damage<sup>4</sup> visible on magnetic resonance imaging (MRI) including white matter hyperintensities (WMH), lacunes, prominent perivascular spaces and microbleeds. Additionally, the damaged endothelium may precipitate local thrombosis and ischaemia, which worsens the damage<sup>4</sup>

Despite the profound health impacts, few RCTs specifically targeted either SVD lesion progression or lacunar stroke.<sup>10</sup> The largest trial in lacunar ischaemic stroke, the Secondary Prevention of Small Subcortical Stroke (SPS3) trial, tested 3.4 years of aspirin+clopidogrel vs aspirin<sup>11</sup> and 3.7 years of target vs guideline blood pressure (BP) reduction<sup>12</sup> in 3020 lacunar ischaemic stroke patients, to prevent recurrent stroke and cognitive decline. The aspirin+clopidogrel vs aspirin arm stopped early due to increased death;<sup>11</sup> target (vs guideline) BP lowering was consistent with a small reduction in recurrent stroke, but neither it nor aspirin+clopidogrel vs aspirin reduced cognitive decline.<sup>13</sup>

Given the long timeline to develop new drugs, available licensed drugs with relevant actions should be evaluated.<sup>10</sup> Prostacyclin (PGI<sub>2</sub>)-cyclic AMP-phosphodiesterase<sup>3</sup> pathway or Nitric oxide (NO)-cyclic GMP-phosphodiesterase<sup>5</sup> modulators may improve vasodilatation, reduce inflammation and smooth muscle hypertrophy and improve cerebral endothelial integrity.<sup>10</sup> Amongst several drugs licensed in Europe, cilostazol and isosorbide mononitrate show promise; two drugs with complementary actions could have synergistic effects.

Cilostazol, a phosphodiesterase 3-inhibitor (PDE3-inhibitor), enhances the PGI<sub>2</sub>-cAMP pathway, with weak antiplatelet effects (so low bleeding risk).<sup>14</sup> Routine cilostazol use reduced

1  
2  
3 dementia incidence in the Taiwanese registry,<sup>15</sup> reduced infarct size<sup>16</sup> and improved myelin  
4 repair in animal models,<sup>17</sup> and has been trialled for secondary stroke prevention in more than  
5 6400 patients.<sup>18-22</sup> Trials where >50% of participants had lacunar stroke (n=4780) found long-  
6 term cilostazol (vs placebo or aspirin) reduced recurrent stroke (OR 0.62, 95%CI 0.49-0.77)  
7 with no evidence of an increase in cerebral haemorrhage (OR 0.52, 95%CI 0.36-0.75), or  
8 death (OR 0.90 95%CI 0.53-1.52) over median one year treatment. However, there are limited  
9 randomised data on cilostazol's effects on cognition or imaging features of SVD, and data are  
10 from Asia-Pacific countries where the epidemiology and risk factors may differ from western  
11 patients.  
12

13  
14 Isosorbide mononitrate (ISMN) is an NO-donating organic nitrate that enhances vasodilation,  
15 is widely used in ischaemic heart disease with a known safety profile and has no antiplatelet  
16 activity.<sup>23</sup> NO maintained cerebral perfusion short term after subacute stroke,<sup>24</sup> but drugs that  
17 increase NO availability are rarely used in stroke.<sup>25</sup>  
18

19  
20 The LACI-1 trial<sup>26</sup> tested short-term dose escalation protocols for cilostazol and ISMN  
21 individually and together, tolerability and early markers of safety and efficacy in patients with  
22 lacunar stroke.<sup>27</sup> LACI-1 recruited 56 patients in two centres, showed that headache, nausea,  
23 palpitations were common pre-randomisation, increased on starting either trial drug, but by  
24 incrementing the dose slowly, symptoms returned to background levels within two weeks.<sup>27</sup>  
25 Most patients achieved the target dose<sup>27</sup> without safety concerns.<sup>28</sup> The LACI-2 trial aims to  
26 determine if cilostazol and ISMN, alone or together, are tolerated at the target dose for a year,  
27 provide feasibility, safety and efficacy data, prior to proceeding to a large phase III trial.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

LACI-2 is a phase IIb randomised, partial factorial, open label, blinded end-point trial, aiming to recruit 400 patients from UK Stroke Network Centres, with follow-up to one year. In addition to experience from LACI-1, LACI-2 trial design benefitted from:

- a National Institutes of Health Research (NIHR) Stroke Research Network (SRN) Portfolio Development Expert Writing Group (members\*);
- the USA NIH-funded SPS3 trial<sup>11,12</sup> (3020 patients with lacunar stroke): Chief Investigator [CI] O Benavente\*;
- the CSPS, CSPS-2 (3740 patients)<sup>18,20</sup> and CSPS-3 trials<sup>22</sup> testing cilostazol to prevent stroke in Japan: CI K Toyoda;
- monogenic SVDs:<sup>29</sup> CI H Chabriat\*;
- the PRESERVE trial:<sup>30</sup> CI H Markus\*;
- the PODCAST trial:<sup>31</sup> CI P Bath\*, Co-CI LACI-2;
- CROMIS- 2 and the Microbleeds International Collaborative Network.<sup>32,33</sup>

The UK SRN Prevention Clinical Studies Group strongly supported testing cilostazol and ISMN in SVD prevention and many UK Clinical Research Network Centres expressed interest in joining LACI-2.

Patients are eligible if they are independent in activities of daily living, have capacity to give consent, are aged over 30 years, have suffered a minor stroke with clinical features compatible with a lacunar syndrome (most frequently, but not limited to, a pure motor hemiparesis, pure sensory stroke, ataxic hemiparesis, sensorimotor stroke, or dysarthria-clumsy hand syndrome; designated as the 'index stroke') and have, on contemporaneous CT or MRI brain imaging, either a visible relevant recent small subcortical (lacunar) infarct or no alternative pathology to explain symptoms (Table1). There is no maximum time limit for recruitment. Exclusion criteria include other significant active neurological illness, alternative pathologies visible on imaging, renal or hepatic impairment, unlikely to complete follow-up due to illness or location, current enrolment in another Clinical Trial of Investigational Medicinal Product (CTIMP), and other general and specific reasons listed in Table 1. Co-enrolment is allowed in non-CTIMPs.

**Table 1.** Inclusion and exclusion criteria

| Inclusion criteria   | Exclusion criteria  |
|--|---|
| <ul style="list-style-type: none"> <li>• Independent in activities of daily living (modified Rankin <math>\leq 2</math>),</li> <li>• Capacity to give consent,</li> <li>• Aged over 30 years,</li> <li>• Minor stroke with clinical features compatible with a lacunar syndrome. Contemporaneous brain imaging shows either:               <ol style="list-style-type: none"> <li>a) a recent, relevant (in time and location) acute small subcortical infarct on MRI diffusion imaging,</li> <li>b) or MR FLAIR, T2 or T1 MR imaging or CT brain imaging <i>shows a recent-appearing small subcortical infarct in a relevant location (i.e. no cavitation or ex-vacuo effect, may be slightly swollen, ill-defined edges),</i></li> <li>c) <i>or MR FLAIR, T2 or T1 MR imaging or CT brain imaging shows a new small subcortical infarct, in a relevant location, appearing between a scan obtained prior to, or just after, the stroke and one done hours to days after the stroke,</i></li> <li>d) or if there is no visible acute small subcortical infarct on MR or CT brain imaging, then there is no alternative pathology as a cause for stroke (i.e. no acute cortical infarct, no acute intracerebral haemorrhage, no stroke mimic such as tumour, subdural haematoma).</li> </ol> </li> </ul> | <p><u>General:</u></p> <ul style="list-style-type: none"> <li>-Other significant active neurological illness e.g. recurrent seizures, multiple sclerosis, brain tumour (well-controlled epilepsy present prior to the stroke, a single seizure at onset of the stroke or provoked seizure is not an exclusion);</li> <li>-Modified Rankin <math>\geq 3</math>;</li> <li>-Formal clinical diagnosis of dementia;</li> <li>-Hypotension, defined as sitting systolic blood pressure <math>&lt; 100</math>mmHg;</li> <li>-Unable to swallow tablets;</li> <li>-Planned surgery during the trial period;</li> <li>-Other concurrent life threatening illness;</li> <li>-Unlikely to be available for follow-up;</li> <li>-History of drug overdose, attempted suicide, significant active mental illness;</li> <li>-Pregnant or breastfeeding women, women of childbearing age not taking contraception;</li> <li>-Renal impairment (creatinine clearance <math>&lt; 25</math> ml/min);</li> <li>-Hepatic impairment;</li> <li>-Current enrolment in another Clinical Trial of Investigational Medicinal Product (CTIMP);</li> <li>-Unable to tolerate, or contraindication to, MRI.</li> </ul> |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Specific to one or other but not both trial drugs (note patients with a contraindication to one trial drug can still be randomised to the other trial drug):

-Definite indication for, or already prescribed, or contraindication to, a trial medication;

Cilostazol:

-Bleeding tendency, e.g. known platelets < 100, active peptic ulcer, history of intracranial haemorrhage (not asymptomatic haemorrhagic transformation of infarction, or a few microbleeds);

-Prescribed anticoagulant medication or dual antiplatelet drugs;

-Prescribed prohibited medications including omeprazole (can be switched to other proton pump inhibitor), erythromycin, clarithromycin, diltiazem, some antifungal or antiviral agents;

-Active cardiac disease (atrial fibrillation, myocardial infarct in last six months, active angina, symptomatic cardiac failure).

Isosorbide mononitrate:

-Lactose intolerance, where site uses ISMN preparations which contain lactose monohydrate;

-prescribed prohibited medications including avanafil, sildenafil, tadalafil, vardenafil.

1  
2  
3 Consent:

4 Participants must have capacity and consent is taken from them for the trial and for secondary  
5 data uses; consent is taken from a relative or other informant to provide outcome data.  
6  
7  
8

9 Intervention:

10 isosorbide mononitrate 40-60mg (or equivalent formulation) daily only; cilostazol 200mg daily  
11 only; or both isosorbide mononitrate 40-60mg and cilostazol 200mg daily. The range of ISMN  
12 doses is allowed to account for different formulations provided in hospital pharmacies. The  
13 trial is open-label since placebo tablets were not available in the UK and masking by  
14 encapsulation was impractical and expensive due to dose escalation and factorial trial design.  
15 However, outcomes including structured symptom questionnaires, ascertainment of clinical  
16 outcomes and MRI analysis are collected by individuals blinded to treatment allocation.  
17 Participants with indications for or contraindications to one drug can be randomised to the  
18 other drug only. The partial factorial design allows testing of both drugs when given alone and  
19 together.  
20  
21  
22  
23  
24  
25  
26  
27

28 Comparator:

29 Best medical guideline stroke prevention therapy as per UK guidelines, which include neither  
30 cilostazol nor ISMN. Throughout the trial, participants continue to take their normal prescribed  
31 medication, information on which is collected at randomisation.  
32  
33  
34  
35

36 Randomisation, minimisation:

37 Randomisation is by central computer-generated allocation at the University of Nottingham  
38 after recording key patient variables and minimisation data. Minimisation uses key prognostic  
39 factors including: age, sex, stroke severity (National Institute of Health Stroke Scale, NIHSS),  
40 dependency resulting from the stroke, systolic BP  $\leq$ / $>$ 140, smoker status, time after stroke,  
41 and years of education. Years of education give an estimate of pre-morbid cognitive ability  
42 and predicts post-stroke cognitive impairment;<sup>9</sup> BP and smoking predict recurrent stroke;  
43 delay since stroke reflects disease activity; age, sex and stroke severity are standard  
44 minimisation variables.<sup>27</sup> This approach ensures concealment of allocation, minimises  
45 differences in key baseline prognostic variables, and improves statistical power.  
46 Randomisation is not minimised by Centre because this may result in high rates of allocation  
47 prediction, but a pre-specified post-hoc analysis by centre will be performed to investigate and  
48 adjust for heterogeneity of treatment effect by centre.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Dispensing:

Participants are allocated in a 1:1 ratio to cilostazol versus no cilostazol and to ISMN versus no ISMN, resulting in a partial factorial comparison of cilostazol versus ISMN versus both drugs versus neither drug. The algorithm generates a unique trial ID and number corresponding to a prescription of allocated trial treatment, which is prepared and dispensed by the local Pharmacy.

### Drug initiation and maintenance:

After randomisation, patients are given instructions to start on a low dose and escalate to target dose over two-to-four weeks. For ISMN, 25mg once daily in the first week, 40-60mg daily in the second week and thereafter. For Cilostazol, 50mg once daily for the first week, twice daily in the second week rising to 100mg twice daily over the next two weeks until participants are on their full dose by one month, remaining on full dose for the rest of the year. Escalation can proceed more slowly if necessary. Participants can remain on less than full dose if they are unable to tolerate the full dose, since some drug may be better than no drug and dose is recorded.

### Assessments:

At baseline, the study researcher records details of the presenting stroke, past medical history, medications, socioeconomic status, education, lifestyle factors, neurological findings, brain imaging findings (index stroke, background WMH, lacunes, microbleeds), blood pressure, cognitive testing (Montreal Cognitive Assessment, Trails B), haematology and biochemistry (Table 2).

After commencing trial treatment, local researchers telephone the participants at 1-2 and 3-4 weeks post randomisation, with intermediary phone calls as necessary, to advise on dose escalation, symptoms, events, check they have achieved full dose or are established on a lower tolerated dose by four weeks.

At six and 12 months, central trial staff (Edinburgh, Nottingham), masked to treatment allocation, perform follow up by postal questionnaire and phone. Additionally, at 12 months, the patient attends their local trial centre for Trails B and brain MRI (to assess SVD lesion burden, new stroke lesions). Information recorded at six and 12 month follow-up includes symptoms, recurrent ischaemic or haemorrhagic stroke or transient ischaemic attack (TIA), cardiac events, smoking status, current medications, modified Rankin scale (mRS), Stroke Impact Scale,<sup>34</sup> and separately the amount of trial medication (Table 2). Date and cause of

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

death are recorded. Participants are encouraged to contact their local Trial Centre to record vascular events occurring between follow-up points.

For Peer Review

**Table 2:** Study Assessments

| <b>Assessment</b>   | <b>Prior to Baseline</b> | <b>Visit 1 Baseline</b> | <b>Week 1-2 FU</b> | <b>Week 3-4 FU</b> | <b>6 month FU</b> | <b>12 month FU</b> |
|---|--------------------------|-------------------------|--------------------|--------------------|-------------------|--------------------|
| Screening for eligibility and Consent <sup>1</sup> ;  | <b>X</b>                 |                         |                    |                    |                   |                    |
| Confirm and document ongoing consent  |                          | <b>X</b>                |                    |                    |                   |                    |
| Medical including drug history  |                          | <b>X</b>                |                    |                    |                   |                    |
| Assess MR or CT diagnostic scan and send a copy to Edinburgh  |                          | <b>X</b>                |                    |                    |                   |                    |
| Randomisation   |                          | <b>X</b>                |                    |                    |                   |                    |
| Haematology (full blood count) and Biochemistry (urea, electrolytes, creatinine)                    |                          | <b>X</b>                |                    |                    |                   |                    |
| Blood Pressure  |                          | <b>X</b>                |                    |                    |                   | <b>X*</b>          |
| Cognitive test: years of education; Montreal Cognitive Assessment (MOCA), timed Trail Making Test B |                          | <b>X</b>                |                    |                    |                   |                    |
| Dispense trial medication <sup>2</sup>  |                          | <b>X</b>                |                    |                    | <b>X</b>          |                    |
| Record symptoms; medication history and IMP adherence   |                          |                         | <b>X</b>           | <b>X</b>           | <b>X</b>          | <b>X</b>           |
| Record recurrent vascular events, mRS, TICS, TMOCA, SIS, ZUNG, * timed Trail Making Test B          |                          |                         |                    |                    | <b>X</b>          | <b>X*</b>          |
| IQCODE (post/phone)   |                          |                         |                    |                    |                   | <b>X</b>           |
| Follow-up brain MRI   |                          |                         |                    |                    |                   | <b>X</b>           |
| Health Economics data: EQ-5D-5L, EQ-VAS   |                          |                         |                    |                    |                   | <b>X</b>           |
| Adverse event reporting as necessary  |                          |                         | <b>X</b>           | <b>X</b>           | <b>X</b>          | <b>X</b>           |

<sup>1</sup>Consent will be obtained before the data collection procedures commence or randomisation is performed. Randomisation occurs at the end of the baseline visit. \* at 12 months in some centres only. <sup>2</sup>Dispensing in 3-monthly intervals is allowed.

FU=follow-up, SIS=Stroke Impact Scale, TICS= Telephone Interview for Cognitive Status, TMOCA= telephone MOCA.

### Brain imaging:

All MR or CT scans performed for stroke diagnosis, to assess new neurological events during the trial, and at one-year follow-up, are collected centrally, anonymised, for blinded assessment. MRI at one year must include diffusion-weighted imaging (DWI), T2-weighted, fluid attenuated inversion recovery (FLAIR), susceptibility-weighted (blood sensitive), and T1-weighted sequences (exemplar sequences are provided). Scans are rated, blind to patient characteristics and treatment allocation, to assess the index infarct location, size, WMH, lacunes, old cortical infarcts, old haemorrhages, microbleeds, siderosis, perivascular spaces and brain atrophy, with validated scores using a web-based system.<sup>5</sup>

Adverse Events are recorded as serious (SAEs), reported to the Sponsor, if they result in hospitalisation, persistent disability, death, or are life threatening. Recurrent vascular events (stroke, myocardial infarction (MI), TIA) and bruising, bleeding or other types of haemorrhage are collected as outcomes, not SAEs. Serious adverse reactions (SARs) and suspected unexpected serious adverse reactions (SUSARS) are also reported. Adverse events (AEs) that are common in patients with stroke and do not meet criteria for seriousness or drug related are recorded.

### Outcomes:

The primary outcome is feasibility, i.e. that eligible participants can be identified correctly, in sufficient numbers, enrolled and >95% retained in follow-up at one year, to achieve target sample of 400 participants in 24 months in the UK. The secondary outcomes are tolerability (can patients tolerate trial medication at least in half dose for up to a year?), safety (systemic or intracranial bleeding, vascular and non-vascular causes of death) and efficacy (stroke, TIA, myocardial ischaemia, cognitive impairment and dementia).

### Sample size:

Data to estimate sample size were limited. Based on LACI-1, we estimated that 75% of participants would take trial medications, in at least half dose, up to one year. We calculated mean annual event rates (Table 3) from trials (SPS3,<sup>11</sup> lacunar participants in ENOS,<sup>25</sup> IST-3,<sup>35</sup> of cilostazol<sup>18,20,36</sup>) and observational data (LADIS;<sup>37</sup> our<sup>9,38,39</sup> and other<sup>40</sup> studies). We expect deaths including vascular deaths of median 2.0% pa, with 4% being the upper 95% CI of 2% in 400 participants.<sup>11</sup> We propose that the absolute risk of death, including fatal haemorrhage, will not exceed 4% per year on trial drugs versus no trial drugs, given in addition to guideline drugs, and will not increase bleeding or ischaemic SVD lesions significantly (at the p<0.01 level) on MRI. LACI-2 therefore has a sample size of 400. Considering a future

1  
2  
3 Phase III trial, recurrent stroke 2.5% pa, MI 0.6% pa and vascular death 1.8% pa,<sup>6,11</sup> (major  
4 adverse cardiovascular events, MACE are infrequent); in contrast, new cognitive impairment  
5 and dependency approximate 16% and 15% respectively at one year,<sup>8,40,41</sup> and are important  
6 to healthcare professionals, patients and carers,<sup>9</sup> thereby justifying their inclusion in a  
7 composite primary outcome. Thus the *combined rate* of recurrent stroke, MI, death, cognitive  
8 impairment and dependency was estimated at 40-50% at one year after enrolment. We  
9 estimate main Phase III trial sample size at 1100 (Table 4), assuming 80% power, alpha 5%,  
10 10% loss to follow-up, composite event rate (45%) and conservative estimate of cilostazol  
11 effect (20% RRR is the lower 95% CI of effect; there were no data for ISMN). A primary  
12 outcome including MRI SVD progression was considered, but at least 15% of participants miss  
13 repeat MRI, sample sizes were similar or larger due to variance in WMH change,<sup>39,42</sup> the cost  
14 of an MRI-based trial is much higher and the WMH intermediary measure is less relevant to  
15 patients.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3** Annual absolute risks (%) of outcome events after lacunar stroke – see text for data sources.

| Vascular death | Non-vascular death | Non-fatal ischaemic stroke or TIA | Non-fatal ICH | MI  | MACE | Dependent (mRS 3-5) | Any cognitive impairment | Dementia |
|----------------|--------------------|-----------------------------------|---------------|-----|------|---------------------|--------------------------|----------|
| 1.8            | 0.5                | 2.5                               | 0.5           | 0.6 | 3    | 15                  | 30                       | 15       |

MI = myocardial infarction, ICH = intracerebral haemorrhage, mRS = modified Rankin Scale, MACE = major adverse cardiovascular events

For Peer Review

**Table 4.** Sample size for composite outcome in main trial, estimated event rates - see text for data sources.

| Composite model                           | A  | B                     | Ci                             | Cii | D                                |
|---|--|-----------------------|--------------------------------|-----|----------------------------------|
| Composite outcome for Phase III includes: | MACE, dementia, non-vasc death, new MR signs | MACE, dementia, death | MACE, cog↓, dependency↓, death |     | MACE, cog imp, depend, all death |
| 1-beta (power)                            | 80%  | 80%                   | 80%                            | 80% | 80%                              |
| Event rate, control, pa                   | 50%  | 10%                   | 30%                            | 30% | 45%                              |
| Relative risk reduction                   | 20%  | 20%                   | 20%                            | 30% | 20%                              |
| Event rate, active, pa                    | 40%  | 8%                    | 24%                            | 21% | 36%                              |
| Total sample size                         | 950  | 6626                  | 1784                           | 778 | 976                              |
| Total trial size, inc losses              | 1250   | 7400                  | 2000                           | 900 | 1100                             |

Assume: 1:1 randomisation and Fleiss adjustment; alpha 5%; primary outcome incomplete in 10%

### Statistical analysis:

A Statistical Analysis Plan (SAP) will be published prior to recruitment ending, blinded to data. A brief summary of planned analyses are as follows. We will compare cilostazol v no cilostazol, ISMN v no ISMN, cilostazol and ISMN v neither, by intention to treat (ITT) analysis. The proportion of patients achieving and sustaining target dose and adverse symptoms will be assessed using odds ratios. ITT analysis will use logistic regression adjusted for minimisation and other baseline prognostic variables (to maximise power<sup>44</sup>) including SVD score, age, and cilostazol+/-ISMN versus control on efficacy and safety outcomes, with secondary tests of subgroup interactions. Ordinal logistic regression will be used for ordinal categorical outcomes (e.g. mRS) to increase power.<sup>43</sup> To analyse safety, we will use Kaplan-Meier and Cox proportional regression for time-to-event outcomes of death, recurrent stroke, MI; binary logistic regression for SAEs, recurrent stroke, MI, and in those completing 12 month MRI, microbleeds, siderosis, new infarcts, and WMH burden.

### Trial and data management

LACI-2 has an operational management committee meeting alternate weeks, a Trial Steering Committee (TSC) with an independent chair, two scientific advisors, participant, funder and sponsor representatives meeting six monthly, a Data Monitoring Committee (DMC) with four independent members meeting yearly, and an International Advisory Board that provides informal advice. The Sponsor, the University of Edinburgh/NHS Lothian joint Academic and Clinical Central Office for Research and Development (ACCORD) approves all trial procedures and provides monitoring. The trial is managed from the Edinburgh Clinical Trials Unit, registered with UKCRC. The secure, password-protected, electronic database and case record form is held at the University of Nottingham; statistical support is provided by the Nottingham Stroke Trials Unit and UKCRC-registered Nottingham Clinical Trials Unit; image data management and analysis is at the University of Edinburgh. Only the DMC members see unblinded data during the trial. Members of each group are listed in the Appendix.

### **Discussion**

LACI-2 is testing drugs that aim to improve the endothelial dysfunction seen in lacunar ischaemic stroke, given for one year. LACI-2 builds on experience in LACI-1 including inclusion and exclusion criteria, data collection, randomisation and statistical analysis, has a similar TSC, the same DMC and International Advisory Boards, to enhance and retain knowledge and experience. LACI-2 will provide methods for balancing randomisation, streamlining of follow-up and reliable data on key event rates for lacunar stroke/SVD trials,

1  
2  
3 preparatory to a Phase III trial of these drugs for definitive efficacy and safety data. LACI-2  
4 aims to promote more personalised approaches to brain vascular disease by recognising and  
5 addressing key mechanistic and susceptibility differences between ischaemic stroke  
6 subtypes.  
7  
8  
9

10  
11 LACI-2 is pragmatic. In LACI-1, target sample 60 patients in two centres, recruitment time was  
12 reduced by 8 months and total cost by £85000 (a third of total available funding) using  
13 enrolment based on CT or MRI compared with only allowing enrolment based on MRI.<sup>27</sup>  
14 Although an MRI-based trial could be more specific for lacunar stroke, we showed that it would  
15 delay trial completion significantly thus inflating staff costs, exclude patients unable to tolerate  
16 MRI, and delay time to finding a treatment for lacunar ischaemic stroke. Since no imaging  
17 modality is perfect, and not all acute ischaemic lesions are visible on MRI even with diffusion  
18 imaging,<sup>45</sup> appropriate use of CT and MRI can exclude alternative causes of symptoms, and  
19 CT can detect moderate to severe WMH, lacunes, atrophy and some old haemorrhages.<sup>46,47</sup>  
20  
21  
22  
23  
24  
25

26  
27 There is no placebo in LACI-2 since, after considerable searching, none was available, but  
28 central follow-up and MRI are blinded to allocation. LACI-2 encourages best medical  
29 management in all patients including good blood pressure control using guideline medications.  
30 Good blood pressure control may help reduce WMH progression<sup>48</sup> and prevents stroke. LACI-  
31 2 is therefore testing cilostazol or ISMN or both plus best medical management versus best  
32 medical management alone.  
33  
34  
35  
36

37  
38 LACI-2 started recruiting in March 2018 in one site, had opened 26 sites and recruited 238  
39 participants by January 2020. Apart from delays in opening sites due to the large  
40 administrative burden of clinical trials, it is on course to complete recruitment by Dec 2020, to  
41 complete follow-up by Dec 2021, and report in spring 2022. The DMC have met twice (August  
42 2018 and 2019) and recruitment continues. To the best of our knowledge, LACI-2 appears to  
43 be the only ongoing trial specifically testing agents for long term prevention of recurrent  
44 lacunar stroke, MACE and worsening of SVD. It is one of only five trials listed in the  
45 Alzheimer's Drug Discovery Foundation Report 2018 (*Drug testing in Dementia*,  
46 <https://www.alzdiscovery.org/research-and-grants/clinical-trials-report>) that is addressing  
47 prevention of vascular dementia.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Feigin VL, Nguyen G, Cercy K, et al. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. *N Engl J Med* 2018; **379**(25): 2429-37.
2. Norrving B, Barrick J, Davalos A, et al. Action Plan for Stroke in Europe 2018–2030. *Eur Stroke J* 2018; **3**(4): 309-36.
3. World Health Organisation. The top 10 causes of death. <http://www.who.int/mediacentre/factsheets/fs310/en/> (accessed January 7 2020).
4. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. *Lancet Neurol* 2019; **18**(7): 684-96.
5. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration: a united approach. *Lancet Neurol* 2013; **12**(8): 822-38.
6. Jackson CA, Hutchison A, Dennis MS, Wardlaw JM, Lewis SC, Sudlow CL. Differences between ischemic stroke subtypes in vascular outcomes support a distinct lacunar ischemic stroke arteriopathy. A prospective, hospital-based study. *Stroke* 2009; **40**: 3679-84.
7. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol* 2017; **134**(2): 171-86.
8. Makin S, Turpin S, Dennis M, Wardlaw J. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke sub-types. *J Neurol Neurosurg Psychiatry* 2013; **84**: 893-900.
9. McHutchison CA, Cvorov V, Makin S, Chappell FM, Shuler K, Wardlaw JM. Functional, cognitive and physical outcomes 3 years after minor lacunar or cortical ischaemic stroke. *J Neurol Neurosurg Psychiatry* 2019; **90**: 436-43.
10. Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. *Int J Stroke* 2015; **10**: 469-78.
11. The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. *N Engl J Med* 2012; **367**: 817-25.
12. SPS3 Study Group, Benavente OR, Coffey CS, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. *Lancet* 2013; **382**: 507-15.
13. Pearce LA, McClure LA, Anderson DC, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. *Lancet Neurol* 2014; **13**: 1177-85.

14. Comerota AJ. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. *Atherosclerosis Supplements* 2006; **6**: 13-9.
15. Tai SY, Chien CY, Chang YH, Yang YH. Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study. *Neurotherapeutics* 2017; **14**(3): 784-91.
16. Pedder H, Vesterinen H, Macleod M, Wardlaw J. A systematic review and meta-analysis of interventions tested in animal models of lacunar stroke. *Stroke* 2014; **45**(2): 563-70.
17. Miyamoto N, Pham LD, Hayakawa K, et al. Age-related decline in oligodendrogenesis retards white matter repair in mice. *Stroke* 2013; **44**(9): 2573-8.
18. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. *J Stroke Cerebrovasc Dis* 2000; **9**(4): 147-57.
19. Uchiyama S, Demaerschalk BM, Goto S, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. *J Stroke Cerebrovasc Dis* 2009; **18**(6): 482-90.
20. Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. *Lancet Neurol* 2010; **9**(10): 959-68.
21. DiNicolantonio JJ, Lavie CJ, Fares H, et al. Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. *Am J Cardiol* 2013; **112**(8): 1230-4.
22. Toyoda K, Uchiyama S, Yamaguchi T, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. *Lancet Neurol* 2019; **18**(6): 539-48.
23. Bath PM, Pathansali R, Iddenden R, Bath FJ. The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke. *Cerebrovasc Dis* 2001; **11**(3): 265-72.
24. Willmot M, Ghadami A, Whysall B, Clarke W, Wardlaw J, Bath PM. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. *Hypertension* 2006; **47**(6): 1209-15.
25. The ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. *Lancet* 2015; **385**: 617-28.
26. Blair GW, Appleton JP, Law ZK, et al. Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary

- 1  
2  
3 endpoints of isosorbide mononitrate and cilostazol, separately and in combination. *Int*  
4 *J Stroke* 2018; **13**(5): 530-8.
- 5  
6 27. Blair GW, Appleton JP, Flaherty K, et al. Tolerability, safety and intermediary  
7 pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined,  
8 in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) Trial,  
9 a randomised clinical trial. *EClinicalMedicine* 2019; **11**: 34-43.
- 10  
11 28. Appleton JP, Blair GW, Flaherty K, et al. Effects of isosorbide mononitrate and/or  
12 cilostazol on haematological markers, platelet function and haemodynamics in patients  
13 with lacunar ischaemic stroke: safety data from the lacunar intervention-1 (LACI-1)  
14 trial. *Front Neurol* 2019; **10**(723).
- 15  
16 29. Chabriat H, Hervé D, Duering M, et al. Predictors of clinical worsening in cerebral  
17 autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy:  
18 prospective cohort study. *Stroke* 2016; **47**(1): 4-11.
- 19  
20 30. Croall ID, Tozer DJ, Moynihan B, et al. Effect of standard vs intensive blood pressure  
21 control on cerebral blood flow in small vessel disease: The PRESERVE randomized  
22 clinical trial. *JAMA Neurol* 2018; **75**(6): 720-7.
- 23  
24 31. Bath PM, Scutt P, Blackburn DJ, et al. Intensive versus Guideline Blood Pressure and  
25 Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention  
26 of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial.  
27 *PLoS One* 2017; **12**(1): e0164608.
- 28  
29 32. Wilson D, Ambler G, Shakeshaft C, et al. Cerebral microbleeds and intracranial  
30 haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic  
31 stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort  
32 study. *The Lancet Neurology* 2018; **17**(6): 539-47.
- 33  
34 33. Wilson D, Ambler G, Lee K, et al. Cerebral microbleeds and stroke risk after ischaemic  
35 stroke or transient ischaemic attack: a pooled analysis of individual patient data from  
36 cohort studies. *Lancet Neurol* 2019; **18**(7): 653-65.
- 37  
38 34. Jenkinson C, Fitzpatrick R, Crocker H, Peters M. The Stroke Impact Scale: validation  
39 in a UK setting and development of a SIS short form and SIS index. *Stroke* 2013; **44**(9):  
40 2532-5.
- 41  
42 35. IST-3 collaborative group. Effect of thrombolysis with alteplase within 6 h of acute  
43 ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]):  
44 18-month follow-up of a randomised controlled trial. *Lancet Neurol* 2013; **12**(8): 768-  
45 76.
- 46  
47 36. Toyoda K, Uchiyama S, Hoshino H, et al. Protocol for Cilostazol Stroke Prevention  
48 Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-  
49 group trial. *Int J Stroke* 2015; **10**(2): 253-8.
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1
- 2
- 3 37. Schmidt R, Berghold A, Jokinen H, et al. White matter lesion progression in LADIS:  
4 frequency, clinical effects, and sample size calculations. *Stroke* 2012; **43**(10): 2643-7.
- 5
- 6 38. Wardlaw JM, Doubal FN, Valdes-Hernandez MC, et al. Blood-brain barrier  
7 permeability and long term clinical and imaging outcomes in cerebral small vessel  
8 disease. *Stroke* 2013; **44**: 525-7.
- 9
- 10
- 11 39. Chappell FM, Del Carmen Valdes Hernandez M, Makin SD, et al. Sample size  
12 considerations for trials using cerebral white matter hyperintensity progression as an  
13 intermediate outcome at 1 year after mild stroke: results of a prospective cohort study.  
14 *Trials* 2017; **18**(1): 78.
- 15
- 16
- 17 40. Pavlovic AM, Pekmezovic T, Tomic G, Trajkovic JZ, Sternic N. Baseline predictors of  
18 cognitive decline in patients with cerebral small vessel disease. *J Alzheimers Dis* 2014;  
19 **42**(Suppl 3): S37-S43.
- 20
- 21
- 22 41. Makin SD, Doubal FN, Shuler K, et al. The impact of early-life intelligence quotient on  
23 post stroke cognitive impairment. *European Stroke Journal* 2018; **3**(2): 145-56.
- 24
- 25 42. Wardlaw JM, Chappell FM, Valdes Hernandez MDC, et al. White matter hyperintensity  
26 reduction and outcomes after minor stroke. *Neurology* 2017; **89**(10): 1003-10.
- 27
- 28 43. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Calculation of sample  
29 size for stroke trials assessing functional outcome: comparison of binary and ordinal  
30 approaches. *Int J Stroke* 2008; **3**: 78-84.
- 31
- 32
- 33 44. The Optimising the Analysis of Stroke Trials (OAST) Collaboration, Gray LJ, Bath PM,  
34 Collier T. Should stroke trials adjust functional outcome for baseline prognostic  
35 factors? *Stroke* 2009; **40**(3): 888-94.
- 36
- 37
- 38 45. Makin SDJ, Doubal FN, Dennis MS, Wardlaw JM. Clinically confirmed stroke with  
39 negative diffusion-weighted imaging magnetic resonance imaging. Longitudinal study  
40 of clinical outcomes, stroke recurrence, and systematic review. *Stroke* 2015; **46**: 3142-  
41 8.
- 42
- 43
- 44 46. Ferguson KJ, Cvoro V, MacLulich AMJ, et al. Visual Rating Scales of White Matter  
45 Hyperintensities and Atrophy: Comparison of Computed Tomography and Magnetic  
46 Resonance Imaging. *J Stroke Cerebrovasc Dis* 2018; **27**(7): 1815-21.
- 47
- 48
- 49 47. Li L, Simoni M, Kuker W, et al. Population-based case-control study of white matter  
50 changes on brain imaging in transient ischemic attack and ischemic stroke. *Stroke*  
51 2013; **44**(11): 3063-70.
- 52
- 53
- 54 48. Nasrallah IM, Pajewski NM, Auchus AP. Association of Intensive vs Standard Blood  
55 Pressure Control With Cerebral White Matter Lesions. *JAMA* 2019; **322**(6): 524-34.
- 56
- 57
- 58
- 59
- 60

1  
2  
3 **Figure 1** CONSORT diagram  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 [INSERT IMAGE HERE]  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

\*Diagnostic MR or CT brain scan assessment (Baseline) refers to a visual assessment of the scan that has already been performed as part of the patient’s routine stroke clinical assessment and diagnosis. Features present on the scan are scored for their presence and severity to create a total sum of small vessel disease score. This is used in the minimisation algorithm.

Dispensing may be at 3-monthly intervals if preferred in particular centres.

## Appendix. The LACI-2 Trial Investigator Group

Writing Committee: Joanna M Wardlaw, Philip MW Bath, Fergus Doubal, Anna Heye, Niki Sprigg, Lisa Woodhouse, Gordon Blair, Jason P Appleton, Vera Cvorov, Timothy J England, Ahamed Hassan, David Werring, Alan Montgomery.

Trial Steering Committee: John Bamford, Independent Chair; Christine Roffe, Stoke, John T. O'Brien, Cambridge, Independent Advisors; Euan Haig, Patient Representative; Joanna M Wardlaw, CI, Fergus Doubal, PI, Edinburgh; Philip MW Bath, Co CI, Nikola Sprigg, Safety Adjudication, Alan Montgomery, Statistical Oversight, Lisa Woodhouse, Statistician, Richard Dooley, Programmer, Nottingham; Timothy England, PI Derby, David Werring, PI UCL London, Ahamed Hassan, PI Leeds, Vera Cvorov, PI Fife; Anna Heye, Trial Manager, Edinburgh; F O'Mahoney, Sponsor Representative, Edinburgh; Shannon Amoils, British Heart Foundation, Funder Representative.

Independent Advisors: Oscar Benavente, Vancouver, Canada; Kasuo Toyoda, Kyoto, Japan; Hugues Chabriat, Paris, France.

Data Monitoring Committee: Colin Baigent, Oxford; Gary Ford, Oxford; Alison D Murray, Aberdeen; Jonathan Emberson, Oxford.

Trial Staff: Anna Heye, Carol Williams, Anna Foster, Kaye Ferguson, Guen Innes, Edinburgh; Di Havard, Sharon Ellender, Patricia Robinson, Lisa Woodhouse, Richard Dooley, Lee Hayward, Nottingham.

Image Management: Eleni Sakka, Image Data Manager, Jeb Palmer, Programmer, David Buchanan, Programmer, Edinburgh.

Independent blinded event adjudication: Nikki Sprigg, Nottingham.

### Participating Sites:

Edinburgh, Royal Infirmary, C001: Fergus Doubal (PI)

Nottingham, University Hospitals, C002: Kailash Krishnan (PI)

Kircaldy, Victoria Hospital, C004: Vera Cvorov (PI)

Glasgow, Queen Elizabeth Hospital, C005: Jesse Dawson (PI)

Bradford, Royal Infirmary, C006: Christopher Patterson (PI)

Aberdeen Royal Infirmary, C007: German Gutierrez (PI)

Leeds General Infirmary, C008: Ahamed Hassan (PI)

Derby, Royal Derby Hospital, C009: Timothy England (PI)

Inverness Raigmore Hospital, C010: Stephen Makin (PI)

London, St George's Hospital, C011: Usman Khan (PI)

London, Kings College Hospital, C012: Laszlo Sztriha (PI)

Essex, Broomfield Hospital, C013: Ramanathan Kirthivasan (PI)

Stockton-on-Tees, University Hospital of North Tees, C014: Anwar Ijaz (PI)

Sheffield, Royal Hallamshire Hospital, C015: Kirsty Harkness (PI)

1  
2  
3 Sandwell, General Hospital, West Bromich, C016: Sissi Ispoglou (PI)  
4 Winchester, Royal Hampshire County Hospital, C017: Nigel Smith (PI)  
5 London, University College, C018: David Werring (PI)  
6 Harrow, Northwick Park Hospital, C019: Aravinth Sivagnanaratnam (PI), David Cohen,  
7 Luton, Luton and Dunstable NHSFT University Hospital, C020: Lakshmanan Sekaran (PI)  
8 Doncaster Royal Infirmary, C021: Dinesh Chadha (PI)  
9 Wolverhampton, New Cross Hospital, C022: Kenneth Fotherby (PI)  
10 Halifax, Calderdale Hospital, C023: Pratap Rana (PI)  
11 Taunton, Musgrove Park Hospital, C025: Malik Hussain (PI)  
12 Southampton General Hospital, C026: Nic Weir (PI)  
13 London, Homerton University Hospital, C027: Thomas Harrison (PI)  
14 Exeter, Royal Devon and Exeter Hospital, C028: Salim Elyas (PI)  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Declarations:**  
4  
5

6 **Conflicting interests:** The authors' institutions receive grants for research; otherwise the  
7 authors declare no conflicts of interest.  
8  
9

10  
11 **Funding:** British Heart Foundation (CS/15/5/31475); the Alzheimer's Society (AS-PG-14-  
12 033), EU Horizon 2020 SVDs@Target (666881, GB), MRC UK DRI, Fondation Leducq (16/05  
13 CVD), NHS Research Scotland, The Stroke Association and Garfield-Weston Foundation  
14 (FD), Chief Scientist Office (UC), National Institute of Health Research (PMB, Senior  
15 Investigator).  
16  
17  
18  
19

20  
21 **Ethical Approval:** The trial is conducted in accordance with the principles of the International  
22 Conference on Harmonisation Tripartite Guideline for Good Clinical Practice (ICH GCP).  
23 Ethics approval was granted by the East Midlands Nottingham 2 Research Ethics Committee  
24 of the Health Research Authority number 17/EM/0077 on 10/05/2017. NHS Research and  
25 Development Approval is given by each participating Centre. The Medicines and Healthcare  
26 Regulatory Authority approved the trial on 01/06/2017. LACI-2 was adopted by the UK Clinical  
27 Research Network and Scottish Stroke Research Network.  
28  
29  
30

31 **Informed consent:** Participants must have capacity and consent is taken from them for the  
32 trial and for secondary data uses; consent is taken from a relative or other informant to provide  
33 outcome data.  
34  
35  
36  
37

38 **Trial Registration:** The trial is registered: EudraCT 2016-002277-35, ISRCTN 14911850.  
39  
40

41 **Guarantor:** JMW  
42  
43


44 **Contributorship:** JMW, PMWB, FD, NS, VC, THE, AH, DW designed the trial and secured  
45 funding; JMW is the Chief Investigator, obtained ethics and regulatory approvals; GB, JPA  
46 helped design the assessments, and with JMW and PMWB, designed the case record form;  
47 AH is the trial manager, responsible for daily running of the trial including regulatory  
48 compliance; FD, THE, AH, DW are Principle Investigators; NS provides independent blinded  
49 event review; AM provides statistical expertise; LW is the trial statistician; JMW drafted the  
50 manuscript; all other authors commented and edited it; all authors approved the final version  
51 for submission.  
52  
53  
54  
55  
56  
57

58 **Acknowledgement:** We thank the patients and their relatives for their time and effort to  
59 participate in LACI-2, the Trial Steering Committee, Sponsor, Data Monitoring Committee,  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Edinburgh Clinical Trials Unit staff, UK Clinical Research Network, Scottish Stroke Research Network, International Advisory Panel, and all staff at participating sites, for their support.

For Peer Review



330x461mm (96 x 96 DPI)